Vericel Corp. (VCEL)
42.36
-0.32
(-0.76%)
USD |
NASDAQ |
Aug 24, 16:00
42.36
0.00 (0.00%)
After-Hours: 19:20
Vericel Price to Book Value : 5.857 for Aug. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 5.902 |
| August 20, 2026 | 5.823 |
| August 19, 2026 | 6.025 |
| August 18, 2026 | 6.120 |
| August 17, 2026 | 6.028 |
| August 14, 2026 | 6.112 |
| August 13, 2026 | 6.159 |
| August 12, 2026 | 6.186 |
| August 11, 2026 | 6.133 |
| August 10, 2026 | 6.078 |
| August 07, 2026 | 6.235 |
| August 06, 2026 | 6.188 |
| August 05, 2026 | 6.273 |
| August 04, 2026 | 6.408 |
| August 03, 2026 | 6.368 |
| July 31, 2026 | 6.356 |
| July 30, 2026 | 6.584 |
| July 29, 2026 | 6.447 |
| July 28, 2026 | 6.459 |
| July 27, 2026 | 6.267 |
| July 24, 2026 | 6.230 |
| July 23, 2026 | 6.229 |
| July 22, 2026 | 6.162 |
| July 21, 2026 | 6.380 |
| July 20, 2026 | 6.344 |
| Date | Value |
|---|---|
| July 17, 2026 | 6.450 |
| July 16, 2026 | 6.611 |
| July 15, 2026 | 6.461 |
| July 14, 2026 | 6.374 |
| July 13, 2026 | 6.567 |
| July 10, 2026 | 6.499 |
| July 09, 2026 | 6.680 |
| July 08, 2026 | 6.502 |
| July 07, 2026 | 6.492 |
| July 06, 2026 | 6.438 |
| July 02, 2026 | 6.497 |
| July 01, 2026 | 6.244 |
| June 30, 2026 | 6.152 |
| June 29, 2026 | 6.454 |
| June 26, 2026 | 6.620 |
| June 25, 2026 | 6.143 |
| June 24, 2026 | 5.970 |
| June 23, 2026 | 5.784 |
| June 22, 2026 | 5.795 |
| June 18, 2026 | 5.742 |
| June 17, 2026 | 5.603 |
| June 16, 2026 | 5.507 |
| June 15, 2026 | 5.483 |
| June 12, 2026 | 5.364 |
| June 11, 2026 | 5.523 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Krystal Biotech, Inc. | 7.442 |
| AbbVie, Inc. | -- |
| Marker Therapeutics, Inc. | 2.056 |
| TG Therapeutics, Inc. | 14.20 |
| ADMA Biologics, Inc. | 5.269 |
Price to Book Value Related Metrics
| PE Ratio | 91.62 |
| PS Ratio | 7.158 |
| PEG Ratio | 0.3380 |
| Price to Free Cash Flow | 35.56 |
| Price | 42.36 |
| Earnings Yield | 1.09% |
| Market Cap | 2.167B |
| PEGY Ratio | 0.3380 |
| Operating PE Ratio | 120.24 |
| Normalized PE Ratio | 91.64 |